Literature DB >> 28586780

Serum Levels of MicroRNA371a-3p: A Highly Sensitive Tool for Diagnosing and Staging Testicular Germ Cell Tumours: A Clinical Case Series.

Petra Anheuser1, Arlo Radtke, Christian Wülfing, Jennifer Kranz, Gazanfer Belge, Klaus-Peter Dieckmann.   

Abstract

INTRODUCTION: MicroRNA (miR)371a-3p was suggested to be a sensitive and specific new serum biomarker of germ cell tumours (GCTs); however, its clinical usefulness remains unproven. PATIENTS,
METHODS: In 312 consecutive cases with various testicular diseases, serum levels of miR371a-3p were measured. Measurement results became available only after completion of treatment. Five patients with testicular seminoma were selected for review because of unanticipated clinical courses.
RESULTS: In each two patients, elevated miR levels heralded undetected primary testicular GCT and metastases despite inconclusive radiological findings. In one case, a normal miR371a-3p level correctly pointed to the absence of metastases contrary to clinical assessment. In all cases, knowledge about the miR371a-3p levels would have altered the clinical management.
CONCLUSIONS: These cases highlight the exceptional usefulness of the new GCT biomarker. In contrast to classical markers, miR371a-3p can identify primary testicular GCT. The marker can aid in clinical decision making in cases with ambiguous clinical findings.
© 2017 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Biomarker; MicroRNA371a-3p; Testicular germ cell tumour; Treatment monitoring

Mesh:

Substances:

Year:  2017        PMID: 28586780      PMCID: PMC5637311          DOI: 10.1159/000477446

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  18 in total

1.  Serum levels of microRNAs miR-371-3: a novel class of serum biomarkers for testicular germ cell tumors?

Authors:  Gazanfer Belge; Klaus-Peter Dieckmann; Meike Spiekermann; Thomas Balks; Jörn Bullerdiek
Journal:  Eur Urol       Date:  2012-02-25       Impact factor: 20.096

Review 2.  Contemporary radiological imaging of testicular cancer.

Authors:  Susan Hilton
Journal:  BJU Int       Date:  2009-11       Impact factor: 5.588

3.  Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.

Authors:  Klaus-Peter Dieckmann; Arlo Radtke; Meike Spiekermann; Thomas Balks; Cord Matthies; Pascal Becker; Christian Ruf; Christoph Oing; Karin Oechsle; Carsten Bokemeyer; Johannes Hammel; Sebastian Melchior; Werner Wosniok; Gazanfer Belge
Journal:  Eur Urol       Date:  2016-08-02       Impact factor: 20.096

4.  MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid.

Authors:  Klaus-Peter Dieckmann; Meike Spiekermann; Thomas Balks; Raphael Ikogho; Petra Anheuser; Werner Wosniok; Thomas Loening; Jörn Bullerdiek; Gazanfer Belge
Journal:  Urol Int       Date:  2016-03-19       Impact factor: 2.089

Review 5.  MicroRNAs in testicular cancer: implications for pathogenesis, diagnosis, prognosis and therapy.

Authors:  Angelika Bezan; Armin Gerger; Martin Pichler
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

6.  Is relative quantification dispensable for the measurement of microRNAs as serum biomarkers in germ cell tumors?

Authors:  Meike Spiekermann; Klaus-Peter Dieckmann; Thomas Balks; Jörn Bullerdiek; Gazanfer Belge
Journal:  Anticancer Res       Date:  2015-01       Impact factor: 2.480

7.  The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989).

Authors:  J P Donohue; J A Thornhill; R S Foster; R Bihrle; R G Rowland; L H Einhorn
Journal:  J Urol       Date:  1995-01       Impact factor: 7.450

Review 8.  State of the art in germ cell tumor imaging.

Authors:  Mustafa Secil; Canan Altay; Isil Basara
Journal:  Urol Oncol       Date:  2015-07-26       Impact factor: 3.498

Review 9.  The present and future of serum diagnostic tests for testicular germ cell tumours.

Authors:  Matthew J Murray; Robert A Huddart; Nicholas Coleman
Journal:  Nat Rev Urol       Date:  2016-10-18       Impact factor: 14.432

10.  Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test).

Authors:  Ton van Agthoven; Leendert H J Looijenga
Journal:  Oncotarget       Date:  2016-07-27
View more
  9 in total

Review 1.  Biomarkers of disease recurrence in stage I testicular germ cell tumours.

Authors:  Peter Lesko; Michal Chovanec; Michal Mego
Journal:  Nat Rev Urol       Date:  2022-08-26       Impact factor: 16.430

2.  The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.

Authors:  Arlo Radtke; Finja Hennig; Raphael Ikogho; Johannes Hammel; Petra Anheuser; Christian Wülfing; Gazanfer Belge; Klaus-Peter Dieckmann
Journal:  Urol Int       Date:  2018-04-26       Impact factor: 2.089

3.  MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.

Authors:  Angelika Terbuch; Jan B Adiprasito; Verena Stiegelbauer; Maximilian Seles; Christiane Klec; Georg P Pichler; Margit Resel; Florian Posch; Anna L Lembeck; Herbert Stöger; Joanna Szkandera; Karl Pummer; Thomas Bauernhofer; Georg C Hutterer; Armin Gerger; Michael Stotz; Martin Pichler
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

4.  Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.

Authors:  Klaus-Peter Dieckmann; Arlo Radtke; Lajos Geczi; Cord Matthies; Petra Anheuser; Ulrike Eckardt; Jörg Sommer; Friedemann Zengerling; Emanuela Trenti; Renate Pichler; Hanjo Belz; Stefan Zastrow; Alexander Winter; Sebastian Melchior; Johannes Hammel; Jennifer Kranz; Marius Bolten; Susanne Krege; Björn Haben; Wolfgang Loidl; Christian Guido Ruf; Julia Heinzelbecker; Axel Heidenreich; Jann Frederik Cremers; Christoph Oing; Thomas Hermanns; Christian Daniel Fankhauser; Silke Gillessen; Hermann Reichegger; Richard Cathomas; Martin Pichler; Marcus Hentrich; Klaus Eredics; Anja Lorch; Christian Wülfing; Sven Peine; Werner Wosniok; Carsten Bokemeyer; Gazanfer Belge
Journal:  J Clin Oncol       Date:  2019-03-15       Impact factor: 44.544

5.  Quantitative PCR Measurement of miR-371a-3p and miR-372-p Is Influenced by Hemolysis.

Authors:  Mette Pernille Myklebust; Benedikte Rosenlund; Peder Gjengstø; Bogdan Stefan Bercea; Ása Karlsdottir; Marianne Brydøy; Olav Dahl
Journal:  Front Genet       Date:  2019-05-22       Impact factor: 4.599

6.  Clinical utility of circulating miR-371a-3p for the management of patients with intracranial malignant germ cell tumors.

Authors:  Matthew J Murray; Thankamma Ajithkumar; Fiona Harris; Rachel M Williams; Ibrahim Jalloh; Justin Cross; Milind Ronghe; Dawn Ward; Cinzia G Scarpini; James C Nicholson; Nicholas Coleman
Journal:  Neurooncol Adv       Date:  2020-04-13

7.  Graded expression of microRNA-371a-3p in tumor tissues, contralateral testes, and in serum of patients with testicular germ cell tumor.

Authors:  Gazanfer Belge; Finja Hennig; Cansu Dumlupinar; Francesca Grobelny; Klaus Junker; Arlo Radtke; Klaus-Peter Dieckmann
Journal:  Oncotarget       Date:  2020-04-21

8.  DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies From Testicular Germ Cell Tumor Patients.

Authors:  José Pedro Sequeira; João Lobo; Vera Constâncio; Tiago Brito-Rocha; Carina Carvalho-Maia; Isaac Braga; Joaquina Maurício; Rui Henrique; Carmen Jerónimo
Journal:  Front Oncol       Date:  2022-06-10       Impact factor: 5.738

9.  MicroRNAs as Appropriate Discriminators in Non-Specific Alpha-Fetoprotein (AFP) Elevation in Testicular Germ Cell Tumor Patients.

Authors:  Anna L Lembeck; Philip Puchas; Georg Hutterer; Dominik A Barth; Angelika Terbuch; Thomas Bauernhofer; Martin Pichler
Journal:  Noncoding RNA       Date:  2020-01-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.